Where Trusted Expertise Meets Real-World Impact

In part two of this topic, Donovan Quill, Bob Gilkin, and Andy Szczotka, discuss critical endpoint measurements—primary, secondary, and surrogate markers—and the challenges manufacturers face in addressing unmet medical needs. They explore the balance of safety and effectiveness, the economic benefits of innovative therapies, and the impact of disappointing trial results. This conversation highlights how finding the right partner to help facilitate the successful design and development of clinical trials plays a pivotal role in ensuring payer, clinical and patient needs are comprehensively managed, enhancing patient access to life-saving treatments.

In part one of this episode, Donovan Quill, Executive Vice President of Business Development, Growth & Strategy; Bob Gilkin, Senior Vice President of Trade and Specialty Strategy; and Andy Szczotka, AscellaHealth’s Chief Pharmacy Officer, discuss what payers are really looking for when it comes to clinical trials and the critical collaboration that’s needed early on between commercial teams and payers in designing clinical trials to improve workflows and pave the way for better patient access.

This first part of our Exclusive Distribution episode kicks off with Donovan Quill, Executive Vice President, Business Development of Growth & Strategy at AscellaHealth and Charlie Gayer, Chief Commercial Officer at BioCryst, discussing the critical factors that influence the decision to adopt an exclusive model of pharmaceutical product distribution; exploring how product characteristics, patient and prescriber profiles, market dynamics, and strategic objectives all play a pivotal role in determining the most suitable distribution strategy.